The World Health Organization (WHO) has issued its first guideline recommending GLP-1 medications as part of treatment programs for obesity, to be used alongside healthy diets, regular physical activity, and counseling. Published in JAMA, the guidance frames obesity as a chronic, relapsing disease affecting more than 1 billion people worldwide and contributing substantially to illness, death, and economic strain. WHO officials said GLP-1 therapies provide clinically meaningful weight loss and broad metabolic benefits, but cautioned that medication alone will not solve the global obesity burden and urged countries to develop comprehensive, equitable obesity programs.
WHO previously emphasized diet and exercise in obesity recommendations but in September added GLP-1 drugs to its list of essential medicines for diabetes. The organization characterized the new obesity guidance as “conditional,” noting that benefits likely outweigh harms while calling for more long-term safety and efficacy data and for prices to fall so access can broaden.
Clinicians and experts welcomed the move while highlighting several caveats. Mir Ali, MD, a bariatric surgeon and medical director at MemorialCare Surgical Weight Loss Center, said the guideline signifies recognition of obesity as a global chronic disease and could incentivize manufacturers to reduce costs and expand availability. Kristin Kirkpatrick, a dietitian, said the guidance marks a shift away from the idea that diet and exercise are the only appropriate options for everyone trying to lose weight, acknowledging that medication plus lifestyle change can be more sustainable for some.
Anil Makam, MD, an associate professor at UCSF, called GLP-1 drugs a “game changer,” noting they are the first truly effective drug class for obesity. He argued the evidence for powerful and consistent weight loss and improvements in obesity-related conditions—especially in people at high cardiovascular risk—is strong, and that the WHO’s conditional stance may understate that evidence. Dan Azagury, MD, of Stanford, described the guideline as important internationally but not groundbreaking. David Cutler, MD, emphasized the broader message that obesity harms health, beyond focus on specific drugs.
How GLP-1 drugs help and which are available
GLP-1 medications mimic a gut hormone that signals fullness to the brain, reducing appetite and intake. Two main drug types among the newer agents are:
– Tirzepatide-containing drugs: examples include Mounjaro and Zepbound. These are dual-action and, in many studies, produce the largest weight loss.
– Semaglutide-containing drugs: examples include Ozempic and Wegovy.
Experts warned against treating all GLP-1s as identical. Makam noted WHO’s guidance grouped GLP-1s together, but tirzepatide-class drugs tend to be more effective (and more costly), a distinction that matters for policymakers.
Benefits beyond weight loss
Research suggests GLP-1 therapies, when combined with diet and exercise, can reduce risks associated with obesity. Studies have linked these drugs to potential reductions in certain cancer risks, lower hospitalization and mortality in some types of heart failure, and even possible benefits for addiction and alcohol use. The magnitude of these benefits varies by drug, dose, population, and duration of treatment.
Access, cost, and equity concerns
High cost, limited production capacity, and supply-chain constraints remain major barriers to broad access. Experts stressed access is a primary obstacle, especially in low- and middle-income countries where availability of drugs, counseling, and comprehensive care is limited. WHO called for policies that improve affordability and ensure integrated, sustainable obesity care systems.
Practical considerations and long-term management
GLP-1 drugs can meaningfully reduce weight, cravings, and appetite. Patients report reduced food preoccupation and healthier choices. Yet these medications often require slow, careful dose escalation and long-term use; significant weight regain commonly occurs after stopping therapy. Side effects—typically gastrointestinal—are common, and long-term safety data are still accruing.
Clinicians recommend starting with diet and exercise and considering medication when lifestyle changes alone are insufficient. Multidisciplinary, longitudinal care—including nutritional and behavioral therapy, medication management, and, when appropriate, surgery—offers the best chance for sustained success. Working with trained professionals helps ensure comprehensive treatment: monitoring doses, managing side effects, addressing dietary patterns, and integrating exercise and other supports.
The scope of obesity and its drivers
In the United States, the CDC estimates about 40% of adults are obese. Obesity raises risks for hypertension, type 2 diabetes, coronary heart disease, stroke, some cancers, sleep apnea, liver and gallbladder disease, pregnancy complications, and depression. Primary drivers include energy-dense diets and excess calorie intake, but genetics, sleep deprivation, stress, aging, and the rise of ultra-processed foods also contribute.
What WHO recommends moving forward
WHO urged nations to incorporate GLP-1 therapies into broader obesity strategies rather than treating them as standalone solutions. The agency emphasized integrating medication with lifestyle interventions, counseling, and policy actions that tackle food environments and social determinants of health. It also highlighted the need for ongoing research into long-term outcomes and cost-effectiveness, and for efforts to reduce drug prices to expand equitable access.
Bottom line
WHO’s guidance acknowledges GLP-1 medications as effective tools in treating obesity within comprehensive care programs, while underscoring that drugs are one component of a multifaceted response. Experts see these therapies as transformative for many patients but stress issues of cost, access, long-term management, and the importance of combining medications with dietary, behavioral, and other medical supports.
